In a filing, Zentalis Pharmaceuticals Inc. revealed its President Gallagher Cam unloaded Company’s shares for reported $0.17 million on Feb 14. In the deal valued at $19.96 per share,8,501 shares were sold. As a result of this transaction, Gallagher Cam now holds 491,270 shares worth roughly $ 9.3 million.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Then, Bunker Kevin D. sold 6,500 shares, generating $129,873 in total proceeds. Upon selling the shares at $19.98, the Chief Scientific Officer now owns 865,157 shares.
Before that, Epperly Melissa B, sold 5,227 shares. Zentalis Pharmaceuticals Inc. shares valued at $104,411 were divested by the Chief Financial Officer at a price of $19.98 per share. As a result of the transaction, Epperly Melissa B, now holds 392,048 shares, worth roughly $7.42 million.
Cowen initiated its Zentalis Pharmaceuticals Inc. [ZNTL] rating to an Outperform in a research note published on Tuesday. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in early April with a ‘”an Overweight”‘ rating. Stifel started covering the stock on September 30, 2021. It rated ZNTL as “a Buy”.
Price Performance Review of ZNTL
On Tuesday, Zentalis Pharmaceuticals Inc. [NASDAQ:ZNTL] saw its stock jump 0.96% to $18.93. On the same session, the stock had its day’s lowest price of $18.35, but rose to a high of $19.22. Over the last five days, the stock has gained 2.05%. Zentalis Pharmaceuticals Inc. shares have fallen nearly -6.01% since the year began. Nevertheless, the stocks have fallen -63.11% over the past one year. While a 52-week high of $52.85 was reached on 01/13/23, a 52-week low of $17.33 was recorded on 01/09/23. SMA at 50 days reached $21.00, while 200 days put it at $23.86. A total of 0.55 million shares were traded, compared to the trading of 0.41 million shares in the previous session.
Levels Of Support And Resistance For ZNTL Stock
The 24-hour chart illustrates a support level at 18.45, which if violated will result in even more drops to 17.96. On the upside, there is a resistance level at 19.32. A further resistance level may holdings at 19.70. The Relative Strength Index (RSI) on the 14-day chart is 38.27, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.93, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 80.26%. Stochastics %K at 12.33% indicates the stock is a buying.
How much short interest is there in Zentalis Pharmaceuticals Inc.?
A steep rise in short interest was recorded in Zentalis Pharmaceuticals Inc. stocks on Jan 12, 2023, growing by 2.31 million shares to a total of 7.87 million shares. Yahoo Finance data shows the prior-month short interest on Dec 14, 2022 was 5.56 million shares. There was a rise of 29.35%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 18.78% of the overall stock float, the days-to-cover ratio (short ratio) rose to 12.47.
Zentalis Pharmaceuticals Inc. [ZNTL] – Who Are The Largest Shareholders?
In filings from Matrix Capital Management Co. LP, it is revealed that the company now owns 9,199,973 shares, or roughly 16.12% of the outstanding ZNTL shares. Additionally, Fidelity Management & Research Co increased 2.47% of its stake after which the total value it holdings stand at $176,402,991, while Avidity Partners Management LP added 21.95% of its stake to hold $121.54 million in the firm. Over the last quarter, The Vanguard Group, Inc. purchased 51,943 shares of Zentalis Pharmaceuticals Inc., while Wellington Management Co. LLP bought 496,129 shares. At present, SSgA Funds Management, Inc. is holding 3,084,137 shares valued at $72.79 million. BlackRock Fund Advisors owned 3,082,865 shares of the company at the time of its most recent 13F filing, worth $72.76 million.
According to FactSet, Zentalis Pharmaceuticals Inc.’s share price will average $39.75 in the next year, based on opinions of analysts polled by the firm. This is up nearly 97.33 percent from its previous closing price of $18.75. Analysts expect Zentalis Pharmaceuticals Inc. stock to reach the higher price of $58.00, while the lowest price estimate is $27.00. However, 5 analysts have rated ZNTL stock as a Buy in their predictions for 2023. The most recent change occurred on September 29, 2021 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $90 price target.